To the full analysis
Acadia Pharmaceuticals stock: growth
ACADAcadia Pharmaceuticals reported $1.07B in revenue for fiscal 2025, up 11.9% on the prior year, up 19.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
29.3%
per year from 2006 to 2025, per share 17.6%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 19.4% | 165.7% | 29.3% |
| Revenue per share | 17.6% | 152.3% | 17.6% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $8.13M | −$45.05M | −$43.44M |
| 2007 | $7.56M | −$56.39M | −$55.34M |
| 2008 | $1.59M | −$64.24M | −$65.1M |
| 2009 | $6.4M | −$45.15M | −$13.77M |
| 2010 | $42.14M | $15.14M | −$10.7M |
| 2011 | $2.07M | −$22.77M | −$19.9M |
| 2012 | $4.91M | −$20.85M | −$21.64M |
| 2013 | $1.15M | −$37.95M | −$32.39M |
| 2014 | $120K | −$92.48M | −$66.61M |
| 2015 | $61K | −$164.44M | −$123.94M |
| 2016 | $17.33M | −$271.39M | −$219.91M |
| 2017 | $124.9M | −$289.4M | −$218.67M |
| 2018 | $223.81M | −$245.19M | −$169.62M |
| 2019 | $339.08M | −$235.26M | −$152.26M |
| 2020 | $441.76M | −$281.58M | −$143.75M |
| 2021 | $484.15M | −$167.87M | −$126.78M |
| 2022 | $517.24M | −$215.98M | −$114.04M |
| 2023 | $726.44M | −$61.29M | −$23.35M |
| 2024 | $957.8M | $226.45M | $157.2M |
| 2025 | $1.07B | $391M | $105.15M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Sep 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.